[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunodeficiencies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunodeficiencies":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,75,109,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":4,"leadSponsor":40,"locationsCount":43},"100054343","studies-of-the-pathogenesis-of-hiv-infection-in-human-peripheral-blood-cells-andor-body-fluids-in-people-living-with-and-without-hiv-100054343",false,"NCT00001281","Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and\u002For Body Fluids in People Living With and Without HIV","* INCLUSION CRITERIA:\n* 18 years of age or older.\n* Adequate venous access.\n* Have a blood pressure less than or equal to 180\u002F100: pulse rate 50-100, unless a lower pulse rate is considered normal for the volunteer.\n* Have adequate blood counts (volunteers living with HIV: hemoglobin greater than or equal to 9.0 g\u002FdL, platelets greater than or equal to 50,000; volunteers living without HIV: hemoglobin greater than or equal to 9.0 g\u002FdL, platelets greater than or equal to 50,000\n* Be willing and able to provide written informed consent on screening, comply with study requirements and procedures, and comply with clinic policies\n* Willingness to allow blood samples to be used for future studies of HIV infection\u002Fpathogenesis, and undergo hepatitis screening\n\nEXCLUSION CRITERIA:\n\n* Pregnant and\u002For breastfeeding females.\n* Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise volunteer safety.",true,"ALL","18 Years","120 Years",{"count":20,"type":21},2419,"ESTIMATED","OBSERVATIONAL","We are studying virologic and\u002For immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-infectious immune regulation and dysregulation using human peripheral blood mononuclear cells as a model.",[25,26,27],"HIV","Immunodeficiencies","Infectious Diseases",[29,30,31,32],"Lymphocytes","Venipuncture","Mononuclear Cells","Natural History","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"1993-03-09",{"name":41,"class":42},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100236493","early-phase-1-expanded-access-protocol-using-cd3cd19-depleted-pbsc-100236493","NCT02356653","Expanded Access Protocol Using CD3+\u002FCD19+ Depleted PBSC","Expanded Access Protocol Using CD3+\u002FCD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells","ExpMACs","Inclusion Criteria:\n\n1. Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+\u002FCD19+ depletion.\n2. Patients with the following transplantable diseases:\n\n   Non-malignant diseases:\n\n   Metabolic storage diseases correctable by HSCT, Bone marrow failure syndromes, Immunodeficiencies\u002Fimmune dysregulation syndromes\u002Fincluding HLH, Hemoglobinopathies correctable and requiring HSCT, and Other diseases treated with HSCT\u002FOther non-malignant blood, metabolic, or immune disorders for which HSCT has been recommended\n\n   Malignant diseases:\n\n   Acute leukemias, Chronic leukemias, Lymphomas, Myelodyplastic syndrome\n3. Signed informed consent\n4. Lansky or Karnofsky performance ≥60\n5. Hematologic and Organ Function per current institutional SOP.\n6. Infectious Evaluation as per current institutional SOP.\n7. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP\n8. In cases that are deemed clinical emergencies (primary or secondary graft failure, severe marrow suppression), the above status criteria will be waived.\n9. Patients must have an identified living donor\n\n   * Donor selection will comply with 21 CFR 1271\n   * Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10\u002F10 match, a 9\u002F10 match, or an 8\u002F10 match if one of the mismatches is at DQB1\n   * Related donor suitable for mobilization infectious disease criteria as per SOP, including HIV, HepB, HepC PCR negative.\n   * CHOP BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.\n   * Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.\n   * The donors selected for this IND will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors; NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases\n\nExclusion Criteria:\n\n1. Uncontrolled bacterial, viral or fungal infections\n2. Suitable, fully HLA matched sibling donor\n3. Donor unable to donate peripheral stem cells\n4. Pregnant participants","30 Years",{"count":54,"type":21},100,"INTERVENTIONAL",[57],"EARLY_PHASE1","The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.",[60,61,62,26,63],"Leukemia","Inborn Errors of Metabolism","Bone Marrow Failure Syndromes","Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome","2026-02-18",{"date":66,"type":37},"2026-02-20",{"date":68,"type":4},"2013-12",{"date":70,"type":21},"2030-01",{"name":72,"class":73},"Children's Hospital of Philadelphia","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":55,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":74},"100589440","phase-3-v-immune-a-novel-immunoglobulin-therapy-for-immunodeficiency-100589440","NCT06954441","V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","V-IMMUNE® for Primary Immunodeficiency: A Phase III Clinical Trial (VIP Study)","VIP","Inclusion Criteria:\n\n* Patients aged 2 years or older;\n* Primary immunoglobulin G deficiency, already receiving another intravenous immunoglobulin (IVIG). Primary IgG deficiency may be secondary (non-exhaustive list) to one of the following diagnoses:\n* Agammaglobulinemia due to absence of B cells\n* Hypogammaglobulinemia with reduced antibody function - variable common immunodeficiency complex\n* Quantitative and functional deficiencies of immunoglobulin G\n* Normal immunoglobulin with reduced capacity for antibody production after immunization (e.g., Wiskott-Aldrich syndrome, IgG subclass deficiency, antipolysaccharide antibody deficiency against Haemophilus or pneumococcus)\n* Severe combined immunodeficiencies: DiGeorge syndrome presenting with immunoglobulin G deficiency\n* Isotype-switching defects: hyperimmunoglobulinemia M syndromes\n* Two trough IgG measurements ≥500 mg\u002FdL within the past 90 days.\n* Participants with through IgG measurements ≥700 mg\u002FdL within the last 30 days before the first visit\n\nExclusion Criteria:\n\n* Acute infection under treatment within 2 weeks prior to screening\n* Pregnancy\n* History of hypersensitivity reaction to blood or blood products\n* Previous anaphylactic reaction to IgG\n* Intolerance to any component of V-Immune\n* IgA deficiency, history of reactions to products containing IgA, or history of anti-IgA antibodies\n* Selective Deficiency of IgA, IgM, IgD, or IgE\n* Participation in any other study involving an investigational product\n* Exposure to blood or any blood-derived products in the last 3 months\n* Known HIV, HCV, or HBV infection\n* ALT \\>3× the upper limit of normal or 3x baseline value\n* Serum creatinine \\>2× the upper limit of normal or 2x baselline value\n* BUN \\>2.5× the upper limit of normal or 2.5x baseline value\n* History of NYHA class III\u002FIV heart failure\n* Uncontrolled hypertension with systolic BP \\>160 mmHg or diastolic BP \\>100 mmHg\n* History of thrombotic events such as DVT, MI, stroke, or PE within the last 6 months\n* Neoplasia under treatment\n* Severe hepatic, renal, or cardiac insufficiency\n* Child-Pugh class B\u002FC hepatic insufficiency\n* Alcohol, opioid, or psychotropic drug abuse within the last 12 months\n* Use of immunosuppressive agents\n* Long-term use of prednisone \\>10 mg\u002Fday or equivalent\n* Protein-losing enteropathies (Crohn's disease, ulcerative colitis, Ménétrier's disease, celiac disease)\n\nObservation:\n\nIf Research participant becomes pregnant during study participation - we will Discontinue any further administration of the IMP; The principal investigator must refer the research participant for follow-up through routine healthcare services; The research participant will continue to be monitored by the study; Obtain informed consent from the pregnant participant to request authorization to follow her pregnancy; If authorized by a specific informed consent form, even after the participant's involvement in the study has ended, the investigator must contact the pregnant participant quarterly to monitor the pregnancy. The results of this follow-up must be entered into the CRF. The frequency will be maintained as long as no abnormalities are identified in the participant, the pregnancy, or the fetus.\n\nFemale partner of a male research participant becomes pregnant during the study = No action is required regarding the research participant's participation; Obtain informed consent from the research participant's partner to request authorization to monitor her pregnancy. If authorized by a specific informed consent form, the investigator must contact the pregnant woman quarterly to monitor the pregnancy. The results of this follow-up must be entered into the CRF. The frequency will be maintained as long as no abnormalities are identified in the pregnant woman, the pregnancy, or the fetus.\n\nData Confidentiality:\n\nThe confidentiality of data from all patients will be ensured and preserved. Patient identification will be performed exclusively through the study-assigned identification number, the patient's initials, and date of birth. An exception to this procedure applies to participants included in the pharmacokinetic analyses, who, after providing consent themselves or through their legal representative, will also have their personal identifying data (full name, CPF \\[Brazilian individual taxpayer registry number\\], date of birth, and sex), as well as information regarding their participation (date of study enrollment), collected and transferred to the ICF laboratory for registration in the SINEB system (Sistema de Informações de Estudos de Equivalência Farmacêutica e Bioequivalência), an ANVISA database used for the registration of participants in studies of this nature.\n\nData obtained from medical records and other documents will be maintained in a confidential manner by the research centers and stored in locations with restricted access limited to the study team. Sensitive data, such as patient contact information collected for scheduling and follow-up purposes, will be accessed exclusively by personnel involved in the conduct of the study. The principal investigator shall allow direct access to participants' records and source documents for the purposes of monitoring, auditing, or inspection by the Sponsor and Regulatory Authorities, if required.\n\nWith regard to participants included in the pharmacokinetic analyses, the collection of personal identifying data (full name, CPF \\[Brazilian individual taxpayer registry number\\], date of birth, and sex) and participation-related information (date of study enrollment) is planned for transfer to the ICF laboratory for registration in the SINEB database. This procedure aims to mitigate risks to research participants by ensuring that they are not concurrently enrolled in another study within an interval shorter than six (6) months.","2 Years",{"count":85,"type":21},50,[87],"PHASE3","This is a phase III, non-randomized clinical trial (VIP Study) designed to assess the safety and efficacy of V-IMMUNE®, a 5% human normal immunoglobulin preparation, in approximately 50 patients with primary immunodeficiency (PID). Participants, all aged ≥2 years and already receiving IVIG therapy, will be switched to V-IMMUNE® at a dose of 600 mg\u002Fkg every three weeks via intravenous infusion. The study will use historical data as a control and extend over 12 months, with scheduled visits at each infusion (an estimated 17 infusions per participant).\n\nObjectives and Outcomes Primary Efficacy Endpoint: Rate of serious bacterial infections over 12 months. Primary Safety Endpoint: Proportion of infusions with one or more temporally associated adverse events (AEs).\n\nSecondary Endpoints: Additional safety outcomes (e.g., average number of AEs within 72 hours per infusion), efficacy measures (non-serious bacterial infections, time to resolution, antibiotic use, hospitalizations), and quality of life (SF-36) at 6 and 12 months. A pharmacokinetic (PK) sub-study will be conducted in 20 participants aged ≥16 years to evaluate total IgG levels, half-life, AUC, Cmax, and other PK parameters.\n\nStudy Design and Intervention V-IMMUNE® is given at an initial infusion rate of 0.01 mL\u002Fkg\u002Fmin for 30 minutes, increasing stepwise up to 0.06 mL\u002Fkg\u002Fmin if well tolerated. Pre-medication, including rapid IV saline, diphenhydramine, and hydrocortisone, will be administered for the first three months to reduce the risk of infusion-related AEs. Patients at elevated thromboembolic risk will receive the lowest feasible infusion rate.\n\nSample Size and Analysis Fifty patients total will be enrolled to ensure adequate power to demonstrate a severe infection rate below one event per person-year (with a one-sided 1% significance level). Safety endpoints will be met if the upper bound of the 95% confidence interval for the proportion of temporally associated infusion-related AEs remains below 40%, assuming a true rate under 20%. An interim analysis is planned at six months or upon reaching 50% enrollment.\n\n20 patients at total including adults and \\\u003C16 years old, 6 children from 2 to 12 years old and 6 children from 12 to 16 years old.",[26,90,91],"Primary Immunodeficiencies (PID)","Agammaglobulinemia",[93,94,95,96,97,98,99],"immunodeficiency","intravenous immunoglobulin","pharmacokinetics","safety","efficacy","serious bacterial infection","temporally related adverse event","2026-01-15",{"date":102,"type":37},"2026-01-20",{"date":104,"type":37},"2025-08-15",{"date":106,"type":21},"2027-02-27",{"name":108,"class":73},"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":55,"phases":118,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":74},"100183644","second-or-greater-allogeneic-hematopoietic-stem-cell-transplant-using-reduced-intensity-conditioning-ric-100183644","NCT01666080","Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)","Inclusion Criteria:\n\n* Diagnosis of any disease for which a second or greater hematopoietic stem cell transplant is needed due to insufficient donor chimerism following hematopoietic recovery after previous HSCT. Determination of \"insufficiency of donor chimerism\" will be made by the treating transplant physician. Occasionally donor derived engraftment may be present, but sustained aplasia or failed recovery of sufficient hematopoiesis requires administration of a second graft. This intervention may be used for both situations.\n* Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program\n\n  * Transplantation using sufficiently matched related donors (such as matched siblings) or unrelated donors will be considered. Both granulocyte-colony stimulating factor (GCSF) stimulated peripheral blood grafts and bone marrow grafts will be considered, although bone marrow will be the priority.\n  * Cord blood grafts, both related and unrelated, are also eligible. As this protocol will use a reduced intensity regimen, this protocol will use the current recommendations of the University of Minnesota for choosing cord blood grafts. If a single cord blood unit cell dose is insufficient, double cord transplantation should be considered if sufficiently matched cord blood units are available. The priority of choosing cord blood donors is based on the current institutional recommendations.\n  * Exclusion of Metabolic Disorder or other Inherited Disorder Carrier Status from related donor and unrelated cord blood grafts as appropriate for primary disease.\n\nAt the discretion of the treating transplant physician, an allograft from the previous donor may be used, if available.\n\n* Age, Performance Status, Consent\n\n  * Age: 0 to 55 years\n  * Consent: voluntary written consent (adult or parental\u002Fguardian)\n\nExclusion Criteria:\n\n* Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of total body irradiation (TBI). Radiation Oncology will evaluate all patients who have had previous radiation therapy or TBI for approval to receive an additional 200 cGy of TBI\n* Pregnant or breastfeeding\n* Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted\n* HIV positive\n* While it would be advantageous to begin therapy on this second transplant regimen \\> 6 months following a prior myeloablative regimen or \\>2 months after a reduced intensity regimen, it is recognized that there are circumstances where this may not be practical.","55 Years",{"count":117,"type":21},30,[119],"NA","This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.",[122,123,26],"Hematologic Disorders","Hemoglobinopathies",[125,126,127,128],"second stem cell transplant","donor hematopoietic engraftment","hematopoietic stem cell transplantation","inherited metabolic disorder","2025-07-23",{"date":131,"type":37},"2025-07-24",{"date":133,"type":37},"2012-08",{"date":135,"type":21},"2027-06",{"name":137,"class":73},"Masonic Cancer Center, University of Minnesota",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":154,"locationsCount":74},"100296942","expanded-access-protocol-using-alphabeta-t-and-cd19-depleted-pbsc-100296942","NCT03145545","Expanded Access Protocol Using Alpha\u002FBeta T and CD19+ Depleted PBSC","Expanded Access Protocol Using TCR Alpha\u002FBeta T Cell\u002FCD19+ Depleted Donor Peripheral Stem Cells","PATIENT AND DONOR ELIGIBILITY\n\nPatients who lack an HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but do not meet criteria for current open institutional protocols using CliniMACs device for β T\u002FCD19+ depletion. Patients with matched related donors including matched sibling donors may also be eligible if special clinical indications are met.\n\nPatients with the following transplantable diseases:\n\nNon-malignant diseases:\n\n* Metabolic storage diseases correctable by HSCT\n* Bone marrow failure syndromes\n* Immunodeficiencies\u002Fimmune dysregulation syndromes\n* Sickle cell disease or thalassemia\n* Other diseases treated with HSCT\n\nMalignant diseases:\n\n* Acute leukemias\n* Chronic leukemias\n* Lymphomas\n* Myelodyplastic syndrome\n\nPatient Eligibility criteria:\n\nIt is important to note that the conditioning prescribed to the patient will be determined based on the disease and organ status and will include agents that are standard. Appropriate combinations of chemotherapy, immunotherapy and\u002For radiation will be determined on an individual basis.\n\nPatient eligibility will be assessed as per our institutional standard operating procedures:\n\n* Signed informed consent\n* Lansky or Karnofsky performance ≥ 60\n* Hematologic and Organ Function as per current institutional SOP\n* Infectious Evaluation as per current institutional SOP\n* Participants of childbearing potential must have a negative pregnancy test as per institutional SOP\n* Subjects with graft failure who require a second HSCT will not need to meet eligibility criteria again prior to the second transplant. Graft failure is a medical emergency that requires HSCT\n\nDonor Eligibility Patients must have an identified living donor\n\n* Donor selection will comply with 21 CFR 1271\\*\n* Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10\u002F10 match, a 9\u002F10 match, or an 8\u002F10 match if one of the mismatches is at DQB1.\n* Related donor mismatched at one to five HLA alleles (haploidentical)\n* Matched related donor may be considered suitable donors for this protocol if a peripheral stem cell donation is deemed by the clinical team to be a safer donation option (if donor is not a suitable candidate for a bone marrow harvest) or if there is concern that bone marrow harvest would not yield adequate cell doses Additionally, a matched related donor would be considered suitable for this protocol if there are safety concerns regarding a patient receiving a standard T cell replete bone marrow transplant due to individualized GVHD risk or risk related to standard GVHD prevention medications.\n* Donor suitable for mobilization of peripheral stem cells and apheresis and fulfills infectious disease criteria as per our institutional SOP, including HIV, HepB, HepC PCR negative.\n* We assess donor eligibility as per our Allogenic Donor Evaluation for Eligibility standard operating procedure. These procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.\n* Related donors will be consented and enrolled under IRB approved research protocol for cell collection per IRB 04-004078 CHP 784 Clinical and Research Collection and Future Research Use of Bone Marrow, Stem Cells or T Cells.\n* Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.\n* The donors selected for this IDE will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors, NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases\n\nExclusion criteria:\n\n* Uncontrolled bacterial, viral, or fungal infections\n* Fully HLA matched sibling donor (fully matched related donors including siblings may be included in special circumstances)\n* Donor unable to donate peripheral stem cells\n* Pregnant Females","1 Month","EXPANDED_ACCESS","The primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia Institutional Review Board (IRB) approved protocols that utilize CliniMACs technology for T depletion.",[60,149,26],"Bone Marrow Failure Syndrome","AVAILABLE","2025-05-18",{"date":153,"type":37},"2025-05-22",{"name":72,"class":73}]